87 related articles for article (PubMed ID: 1392166)
1. Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease.
Filella X; Molina R; Jo J; Bedini JL; Joseph J; Ballesta AM
Bull Cancer; 1992; 79(3):271-7. PubMed ID: 1392166
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of TAG-72 as a serum marker in ovarian and breast carcinoma.
Esposito G; Panza N; Mansi L; De Matteis A; D'Aiuto G; Labonia V; Riccardi F; Pacilio G; Salvatore M
J Nucl Med Allied Sci; 1990; 34(2):88-93. PubMed ID: 2246676
[TBL] [Abstract][Full Text] [Related]
3. [Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4].
Ohuchi N; Matoba N; Taira Y; Takahashi K; Sakai N; Sato K; Fujita N; Mochizuki F; Nishihira T; Mori S
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2767-72. PubMed ID: 3166366
[TBL] [Abstract][Full Text] [Related]
4. Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay.
Guadagni F; Roselli M; Cosimelli M; Spila A; Cavaliere F; Tedesco M; Arcuri R; Abbolito MR; Casale V; Pericoli MN; Vecchione A; Casciani CU; Greiner JW; Schlom J
Cancer Res; 1996 Nov; 56(22):5293-8. PubMed ID: 8912871
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of the new tumor marker TAG-72.
Guadagni F; Roselli M; Ferroni P; Amato T; Colcher D; Greiner JW; Schlom J
Anticancer Res; 1991; 11(4):1389-94. PubMed ID: 1746895
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
7. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3.
Thor A; Ohuchi N; Szpak CA; Johnston WW; Schlom J
Cancer Res; 1986 Jun; 46(6):3118-24. PubMed ID: 3516392
[TBL] [Abstract][Full Text] [Related]
8. CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma.
Guadagni F; Roselli M; Amato T; Cosimelli M; Perri P; Casale V; Carlini M; Santoro E; Cavaliere R; Greiner JW
Cancer Res; 1992 Mar; 52(5):1222-7. PubMed ID: 1737383
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3.
Thor A; Gorstein F; Ohuchi N; Szpak CA; Johnston WW; Schlom J
J Natl Cancer Inst; 1986 Jun; 76(6):995-1006. PubMed ID: 3520078
[TBL] [Abstract][Full Text] [Related]
10. Comparison of serum assays for TAG-72, CA19-9 and CEA in gastrointestinal carcinoma patients.
Ohuchi N; Takahashi K; Matoba N; Sato T; Taira Y; Sakai N; Masuda M; Mori S
Jpn J Clin Oncol; 1989 Sep; 19(3):242-8. PubMed ID: 2810823
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
12. Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique.
Ren J; Chen Z; Juan SJ; Yong XY; Pan BR; Fan DM
Cancer; 2000 Jan; 88(2):280-5. PubMed ID: 10640958
[TBL] [Abstract][Full Text] [Related]
13. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis.
Ponnusamy MP; Venkatraman G; Singh AP; Chauhan SC; Johansson SL; Jain M; Smith L; Davis JS; Remmenga SW; Batra SK
Cancer Lett; 2007 Jun; 251(2):247-57. PubMed ID: 17210225
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
15. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
Bray KR; Koda JE; Gaur PK
Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
[TBL] [Abstract][Full Text] [Related]
16. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
[TBL] [Abstract][Full Text] [Related]
17. [The value of serum tumor-associated glycoprotein 72 (TAG 72) in the diagnosis of malignancies].
Sun G
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Dec; 14(6):447-50. PubMed ID: 1303818
[TBL] [Abstract][Full Text] [Related]
18. Nonspecific cross-reacting antigen 50/90 is elevated in patients with breast, lung, and colon cancer.
Allard WJ; Neaman IE; Elting JJ; Barnett TR; Yoshimura H; Fritsche HA; Yeung KK
Cancer Res; 1994 Mar; 54(5):1227-34. PubMed ID: 8118811
[TBL] [Abstract][Full Text] [Related]
19. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365
[TBL] [Abstract][Full Text] [Related]
20. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
